Gardner Lewis Asset Management L P Incyte Corp Transaction History

Gardner Lewis Asset Management L P

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 13, 2018	SELL	$60.85 - $83.98 $2.28 Million - $3.14 Million	-37,401 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$83.06 - $100.98 $540,305 - $656,874	-6,505 Reduced 14.82%	37,401 $3.12 Million
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $629,939 - $785,067	6,733 Added 18.11%	43,906 $4.16 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $817,642 - $1.04 Million	7,491 Added 25.24%	37,173 $4.34 Million
Q2 2017 Aug 14, 2017	BUY	N/A	29,682	29,682 $3.74 Million

641

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.9B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Gardner Lewis Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Gardner Lewis Asset Management L P with notifications on news.